East Lyme, Connecticut, USA: Analysis from Phesi shows the impact of COVID-19 on clinical development is continuing to mount, with many clinical trial sites unable to bounce back following suspension in March and April 2020
East Lyme, Connecticut, USA: Phesi, a data-driven provider of clinical development analytics products and solutions, today announced a new country selection functionality has been added to ClinSite, its platform to provide investigator site intelligence to clients, enabling investigator site selection and management. The new functionality has been added in response to the industry-wide problem of non-performing countries and sites being…
EAST LYME, Conn. Phesi, a data-driven provider of premier integrated clinical development analytics products and services, today announced that OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS) has purchased a multi-year ClinSite™ license to enable more accurate and precise planning for Phase 2 and 3 clinical trials of anticancer immunotherapies developed with OncoSec’s plasmid DNA delivery platform. ClinSite is a self-service, artificial intelligence (AI)-powered…
EAST LYME, Conn. Phesi is delighted to announce the appointment of Dan Manak to the role of Executive Director for Business Development. Dan is based in the US and has been working in pharma and clinical research for over 20 years, selling advanced clinical data analytics and AI technology and services to sponsor companies, enabling site selection and site management. On…
Journalist Dick Anderson conducted an interview with Dr. Gen Li, founder and president of Phesi. Gen Li was an instructor of neuroscience at Weill Cornell Medicine in 1996 when he enrolled in the inaugural class of Johnson’s One-Year MBA program for students with advanced technology degrees. He recalls a team-building session when a peer said, “Gen, you have an amazing capability in seeing…